(TRS) TriMas - Overview
Sector: Consumer Cyclical | Industry: Packaging & Containers | Exchange: NASDAQ (USA) | Market Cap: 1.401m USD | Total Return: 51.7% in 12m
Avg Turnover: 18.8M
EPS Trend: 34.6%
Qual. Beats: -1
Rev. Trend: -48.3%
Qual. Beats: 0
Warnings
P/E ratio 111.7
Below Avwap Earnings
Tailwinds
No distinct edge detected
TriMas Corporation (NASDAQ: TRS) is a global manufacturer serving the consumer products, aerospace, defense, and industrial sectors. The company operates through two primary segments: Packaging and Specialty Products. Its Packaging division focuses on high-volume dispensing systems, closures, and medical components for the food, beverage, and healthcare markets. The Specialty Products division, operating under the Norris Cylinder brand, produces steel cylinders for the storage and transport of compressed gases.
The company utilizes a diversified distribution model, leveraging a direct sales force alongside third-party agents and distributors to reach international markets. As a player in the Industrial Machinery and Components sector, TriMas relies on material science and precision engineering to maintain its competitive position in niche manufacturing. Investors can evaluate the companys historical performance and valuation metrics on ValueRay.
Headquartered in Bloomfield Hills, Michigan, TriMas has expanded its portfolio through the acquisition of established brands such as Rieke and Taplast. This strategy allows the firm to capture value across various stages of the supply chain, from diagnostic test components to industrial gas infrastructure.
- Shift toward high-margin pharmaceutical and beauty packaging drives overall segment profitability
- Global demand for industrial gas cylinders influences Specialty Products revenue growth
- Raw material cost volatility for polymers and steel impacts manufacturing margins
- Strategic acquisitions in specialized packaging markets expand global market share footprint
- Aerospace and defense sector recovery accelerates precision component sales volume
| Net Income: 908.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.41 > 0.02 and ΔFCF/TA 37.16 > 1.0 |
| NWC/Revenue: 145.5% < 20% (prev 38.85%; Δ 106.6% < -1%) |
| CFO/TA 0.04 > 3% & CFO 88.9m > Net Income 908.5m |
| Net Debt (-827.7m) to EBITDA (192.9m): -4.29 < 3 |
| Current Ratio: 4.85 > 1.5 & < 3 |
| Outstanding Shares: last quarter (37.4m) vs 12m ago -8.65% < -2% |
| Gross Margin: 22.62% > 18% (prev 0.20%; Δ 2.24k% > 0.5%) |
| Asset Turnover: 47.02% > 50% (prev 55.39%; Δ -8.37% > 0%) |
| Interest Coverage Ratio: 4.93 > 6 (EBITDA TTM 192.9m / Interest Expense TTM 18.8m) |
| A: 0.55 (Total Current Assets 1.59b - Total Current Liabilities 327.5m) / Total Assets 2.30b |
| B: 0.40 (Retained Earnings 917.1m / Total Assets 2.30b) |
| C: 0.05 (EBIT TTM 92.5m / Avg Total Assets 1.85b) |
| D: 1.08 (Book Value of Equity 917.3m / Total Liabilities 847.3m) |
| Altman-Z'' = 6.38 = AAA |
| DSRI: 0.62 (Receivables 128.6m/183.8m, Revenue 867.8m/772.0m) |
| GMI: 0.87 (GM 22.62% / 19.69%) |
| AQI: 0.46 (AQ_t 0.19 / AQ_t-1 0.40) |
| SGI: 1.12 (Revenue 867.8m / 772.0m) |
| TATA: 0.36 (NI 908.5m - CFO 88.9m) / TA 2.30b) |
| Beneish M = -3.32 (Cap -4..+1) = AA |
As of May 25, 2026, the stock is trading at USD 39.10 with a total of 425,679 shares traded.
Over the past week, the price has changed by +5.50%,
over one month by +8.77%,
over three months by +10.44% and
over the past year by +51.66%.
TriMas has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy TRS.
- StrongBuy: 1
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 45 | 15.1% |
P/E Forward = 23.4192
P/S = 2.1176
P/B = 0.969
P/EG = 1.9395
Revenue TTM = 867.8m USD
EBIT TTM = 92.5m USD
EBITDA TTM = 192.9m USD
Long Term Debt = 396.6m USD (from longTermDebt, last quarter)
Short Term Debt = 7.19m USD (from shortTermDebt, last quarter)
Debt = 481.9m USD (from shortLongTermDebtTotal, last quarter) + Leases 42.7m
Net Debt = -827.7m USD (calculated: Debt 481.9m - CCE 1.31b)
Enterprise Value = 573.2m USD (1.40b + Debt 481.9m - CCE 1.31b)
Interest Coverage Ratio = 4.93 (Ebit TTM 92.5m / Interest Expense TTM 18.8m)
EV/FCF = 0.61x (Enterprise Value 573.2m / FCF TTM 937.3m)
FCF Yield = 163.5% (FCF TTM 937.3m / Enterprise Value 573.2m)
FCF Margin = 108.0% (FCF TTM 937.3m / Revenue TTM 867.8m)
Net Margin = 104.7% (Net Income TTM 908.5m / Revenue TTM 867.8m)
Gross Margin = 22.62% ((Revenue TTM 867.8m - Cost of Revenue TTM 671.5m) / Revenue TTM)
Gross Margin QoQ = 21.03% (prev 21.17%)
Tobins Q-Ratio = 0.25 (Enterprise Value 573.2m / Total Assets 2.30b)
Interest Expense / Debt = 3.89% (Interest Expense 18.8m / Debt 481.9m)
Taxrate = 21.0% (US default 21%)
NOPAT = 73.1m (EBIT 92.5m * (1 - 21.00%))
Current Ratio = 2.67 (Total Current Assets 1.59b / Total Current Liabilities 594.7m)
Debt / Equity = 0.33 (Debt 481.9m / totalStockholderEquity, last quarter 1.45b)
Debt / EBITDA = -4.29 (Net Debt -827.7m / EBITDA 192.9m)
Debt / FCF = -0.88 (Net Debt -827.7m / FCF TTM 937.3m)
Total Stockholder Equity = 898.9m (last 4 quarters mean from totalStockholderEquity)
RoA = 49.23% (Net Income 908.5m / Total Assets 2.30b)
RoE = 101.1% (Net Income TTM 908.5m / Total Stockholder Equity 898.9m)
RoCE = 7.14% (EBIT 92.5m / Capital Employed (Equity 898.9m + L.T.Debt 396.6m))
RoIC = 6.15% (NOPAT 73.1m / Invested Capital 1.19b)
WACC = 7.02% (E(1.40b)/V(1.88b) * Re(8.38%) + D(481.9m)/V(1.88b) * Rd(3.89%) * (1-Tc(0.21)))
Discount Rate = 8.38% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -64.44 | Cagr: -4.61%
[DCF] Terminal Value 77.97% ; FCFF base≈582.7m ; Y1≈667.9m ; Y5≈983.0m
[DCF] Fair Price = 436.0 (EV 14.8b - Net Debt -827.7m = Equity 15.6b / Shares 35.8m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 34.59 | EPS CAGR: 3.36% | SUE: -3.33 | # QB: -1
Revenue Correlation: -48.35 | Revenue CAGR: -2.66% | SUE: 0.07 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.49 | Chg30d=+6.13% | Revisions=+33% | Analysts=2
EPS next Quarter (2026-09-30): EPS=0.52 | Chg30d=+1.56% | Revisions=+0% | Analysts=2
EPS current Year (2026-12-31): EPS=1.67 | Chg30d=+6.46% | Revisions=+33% | GrowthEPS=-20.0% | GrowthRev=-34.8%
EPS next Year (2027-12-31): EPS=2.17 | Chg30d=+4.33% | Revisions=+20% | GrowthEPS=+29.7% | GrowthRev=+5.0%
[Analyst] Revisions Ratio: +33%